JP2010534627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534627A5 JP2010534627A5 JP2010517324A JP2010517324A JP2010534627A5 JP 2010534627 A5 JP2010534627 A5 JP 2010534627A5 JP 2010517324 A JP2010517324 A JP 2010517324A JP 2010517324 A JP2010517324 A JP 2010517324A JP 2010534627 A5 JP2010534627 A5 JP 2010534627A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 241000272478 Aquila Species 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 108010017271 denileukin diftitox Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940056913 eftilagimod alfa Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229940100027 ontak Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07014796.2 | 2007-07-27 | ||
| EP07014796 | 2007-07-27 | ||
| US95310907P | 2007-07-31 | 2007-07-31 | |
| US60/953,109 | 2007-07-31 | ||
| US98124107P | 2007-10-19 | 2007-10-19 | |
| US60/981,241 | 2007-10-19 | ||
| PCT/EP2008/006152 WO2009015841A1 (en) | 2007-07-27 | 2008-07-25 | Composition of tumour-associated peptides and related anti-cancer vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013061688A Division JP5746251B2 (ja) | 2007-07-27 | 2013-03-25 | 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534627A JP2010534627A (ja) | 2010-11-11 |
| JP2010534627A5 true JP2010534627A5 (enExample) | 2011-11-17 |
| JP5352586B2 JP5352586B2 (ja) | 2013-11-27 |
Family
ID=39926464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517324A Expired - Fee Related JP5352586B2 (ja) | 2007-07-27 | 2008-07-25 | 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物 |
| JP2013061688A Expired - Fee Related JP5746251B2 (ja) | 2007-07-27 | 2013-03-25 | 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013061688A Expired - Fee Related JP5746251B2 (ja) | 2007-07-27 | 2013-03-25 | 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7994276B2 (enExample) |
| EP (2) | EP2567707B1 (enExample) |
| JP (2) | JP5352586B2 (enExample) |
| KR (1) | KR101167392B1 (enExample) |
| CN (2) | CN103360466B (enExample) |
| AU (1) | AU2008281013B2 (enExample) |
| BR (1) | BRPI0814140A2 (enExample) |
| CA (2) | CA2817054C (enExample) |
| DK (1) | DK2567707T3 (enExample) |
| EA (2) | EA018457B1 (enExample) |
| ES (1) | ES2608583T3 (enExample) |
| HU (1) | HUE032379T2 (enExample) |
| LT (1) | LT2567707T (enExample) |
| MX (1) | MX2010001088A (enExample) |
| NZ (1) | NZ582823A (enExample) |
| PL (1) | PL2567707T3 (enExample) |
| PT (1) | PT2567707T (enExample) |
| SI (1) | SI2567707T1 (enExample) |
| UA (2) | UA103882C2 (enExample) |
| WO (1) | WO2009015841A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| CN103360466B (zh) * | 2007-07-27 | 2016-08-03 | 伊玛提克斯生物技术有限公司 | 抗肿瘤相关肽及相关抗癌疫苗组合物 |
| PL2119726T5 (pl) * | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| SG2014012363A (en) * | 2011-10-28 | 2014-09-26 | Oncotherapy Science Inc | Topk peptides and vaccines including the same |
| HK1207667A1 (en) * | 2012-05-08 | 2016-02-05 | Western University Of Health Sciences | Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| TWI636065B (zh) * | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| CN104630145A (zh) * | 2015-01-12 | 2015-05-20 | 杨世成 | 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物 |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| TWI772927B (zh) * | 2015-03-31 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架 |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| CN104926944B (zh) * | 2015-05-22 | 2018-04-13 | 北京康爱瑞浩生物科技股份有限公司空港分公司 | 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| CN108026154B (zh) | 2015-07-01 | 2022-03-08 | 伊玛提克斯生物技术有限公司 | 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201512703D0 (en) | 2015-07-20 | 2015-08-26 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| SG11201804957VA (en) | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| CN105586312A (zh) * | 2016-02-29 | 2016-05-18 | 时宏珍 | Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法 |
| WO2018064215A1 (en) * | 2016-09-27 | 2018-04-05 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| JP7346302B2 (ja) * | 2017-03-28 | 2023-09-19 | オハイオ・ステイト・イノベーション・ファウンデーション | ヒトｐｄ－１ペプチドワクチン及びその使用法 |
| CA3059645A1 (en) * | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| CR20210159A (es) * | 2017-04-10 | 2021-05-21 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508) |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
| GB201810358D0 (en) * | 2018-06-25 | 2018-08-08 | Univ College Cardiff Consultants Ltd | Cancer-specific t-cell receptors |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| BR112022001688A2 (pt) * | 2019-07-30 | 2022-05-24 | Univ Health Network | Receptores de células t e métodos de uso dos mesmos |
| CA3161242A1 (en) * | 2019-12-18 | 2021-06-24 | Birgitte Rono | Nucleic acid vaccination using neo-epitope encoding constructs |
| CN111363009B (zh) * | 2020-03-18 | 2020-10-30 | 北京鼎成肽源生物技术有限公司 | 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用 |
| CN111617238B (zh) * | 2020-06-02 | 2022-12-13 | 苏州药明康德新药开发有限公司 | 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA725596A (en) | 1960-08-26 | 1966-01-11 | J. Wretlind Arvid | Method of preparing intravenously injectable fat emulsions free from side reactions or complications |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US4803261A (en) * | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| JPH02107189A (ja) * | 1988-05-25 | 1990-04-19 | City Of Hope | 癌胎児抗原フラグメント |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1017810B1 (en) | 1997-10-10 | 2004-05-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| US6756038B1 (en) * | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| US6623923B1 (en) * | 1998-12-23 | 2003-09-23 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| AU7721500A (en) * | 1999-09-29 | 2001-04-30 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| CA2411278A1 (en) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030017167A1 (en) * | 2000-06-09 | 2003-01-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20020102544A1 (en) * | 2000-09-15 | 2002-08-01 | David Mack | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| CA2431313A1 (en) * | 2000-12-08 | 2002-08-01 | Eos Biotechnology, Inc. | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| CA2459219A1 (en) * | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| IL164281A0 (en) * | 2002-04-01 | 2005-12-18 | Euro Celtique Sa | Epitope constructs comprising antigen presenting cell targeting mechanisms |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| WO2004014867A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| EP1581812B1 (en) * | 2003-01-06 | 2008-07-16 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
| JP2007523610A (ja) * | 2003-05-05 | 2007-08-23 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 癌胎児抗原をコードする合成遺伝子およびその使用 |
| CN1727362B (zh) * | 2004-07-30 | 2010-12-01 | 中国人民解放军第二军医大学 | 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用 |
| EP1786906A2 (en) * | 2004-09-09 | 2007-05-23 | Exonhit Therapeutics SA | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis |
| SI1642905T1 (sl) | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop |
| ITRM20050064A1 (it) * | 2005-02-16 | 2006-08-17 | Univ Siena | Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative. |
| ES2367643T3 (es) * | 2005-04-26 | 2011-11-07 | Immatics Biotechnologies Gmbh | Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este. |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| ATE461215T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| US8298544B2 (en) * | 2006-02-27 | 2012-10-30 | Gal Markel | CEACAM based antibacterial agents |
| CN103360466B (zh) * | 2007-07-27 | 2016-08-03 | 伊玛提克斯生物技术有限公司 | 抗肿瘤相关肽及相关抗癌疫苗组合物 |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| PL2119726T5 (pl) * | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
-
2008
- 2008-07-25 CN CN201310109229.4A patent/CN103360466B/zh not_active Expired - Fee Related
- 2008-07-25 EP EP12187307.9A patent/EP2567707B1/en active Active
- 2008-07-25 ES ES12187307.9T patent/ES2608583T3/es active Active
- 2008-07-25 WO PCT/EP2008/006152 patent/WO2009015841A1/en not_active Ceased
- 2008-07-25 NZ NZ582823A patent/NZ582823A/en not_active IP Right Cessation
- 2008-07-25 PL PL12187307T patent/PL2567707T3/pl unknown
- 2008-07-25 KR KR1020107001771A patent/KR101167392B1/ko not_active Expired - Fee Related
- 2008-07-25 CA CA2817054A patent/CA2817054C/en not_active Expired - Fee Related
- 2008-07-25 EA EA201000208A patent/EA018457B1/ru not_active IP Right Cessation
- 2008-07-25 JP JP2010517324A patent/JP5352586B2/ja not_active Expired - Fee Related
- 2008-07-25 US US12/180,113 patent/US7994276B2/en active Active
- 2008-07-25 EA EA201300322A patent/EA023928B1/ru not_active IP Right Cessation
- 2008-07-25 MX MX2010001088A patent/MX2010001088A/es active IP Right Grant
- 2008-07-25 SI SI200831735A patent/SI2567707T1/sl unknown
- 2008-07-25 CN CN200880100807.5A patent/CN101765434B/zh not_active Expired - Fee Related
- 2008-07-25 PT PT121873079T patent/PT2567707T/pt unknown
- 2008-07-25 UA UAA201001960A patent/UA103882C2/uk unknown
- 2008-07-25 DK DK12187307.9T patent/DK2567707T3/da active
- 2008-07-25 HU HUE12187307A patent/HUE032379T2/en unknown
- 2008-07-25 UA UAA201302331A patent/UA117216C2/uk unknown
- 2008-07-25 EP EP08785105.1A patent/EP2178557B1/en active Active
- 2008-07-25 AU AU2008281013A patent/AU2008281013B2/en not_active Ceased
- 2008-07-25 BR BRPI0814140A patent/BRPI0814140A2/pt not_active IP Right Cessation
- 2008-07-25 CA CA2694771A patent/CA2694771A1/en not_active Abandoned
- 2008-07-25 LT LTEP12187307.9T patent/LT2567707T/lt unknown
-
2013
- 2013-03-25 JP JP2013061688A patent/JP5746251B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534627A5 (enExample) | ||
| JP2013522276A5 (enExample) | ||
| US20230390381A1 (en) | Immunogenic combinations | |
| Weinberger et al. | Vaccines for the elderly | |
| JP2013530157A5 (enExample) | ||
| HRP20170115T1 (hr) | Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma | |
| RU2021122284A (ru) | Составы вакцин против неоплазии и способы их получения | |
| ES2594758T3 (es) | Procedimientos de vacunación contra la malaria | |
| JP6032853B2 (ja) | 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法 | |
| JP2014521687A5 (enExample) | ||
| JP2016518355A5 (enExample) | ||
| JP2007508272A5 (enExample) | ||
| EA202091233A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| HRP20110965T1 (hr) | Nove formulacije peptida povezanih s tumorima koji se vežu za molekule ljudskog leukocitnog antigena (hla) klase i ili ii za cjepiva | |
| JP2012526853A5 (enExample) | ||
| BRPI0713711A2 (pt) | vacina viral recombinante, kit para vacinação, e, método para usar pelo menos um composto | |
| JP2014502156A5 (enExample) | ||
| JP2015533376A5 (enExample) | ||
| JP2008530975A5 (enExample) | ||
| JP2018532782A5 (enExample) | ||
| RU2018120009A (ru) | Способ вакцинации против аутоантигена у пациента-человека | |
| JP2014508734A5 (enExample) | ||
| JP2014521605A5 (enExample) | ||
| JP2014139185A5 (enExample) | ||
| RU2015115785A (ru) | Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака |